@trtstrong's TRT experience claims need context

What did @trtstrong actually say?

At around 45, after a gym friend mentioned his testosterone was lower than his wife's, @trtstrong got his levels checked and came back around 200 ng/dL. He tried pellets for about a year, switched to injections partly for cost reasons, and claims three years of continuous muscle gains he never saw in 30 years of lifting before TRT. He puts the "peak" target range at 1,000-1,200 ng/dL and pushes back on the fear that starting TRT means your body stops making its own testosterone, arguing that if your body isn't producing useful levels anyway, the concern is moot.

He's speaking from personal experience, not as a clinician, and he's reasonably upfront about that. Still, several of his claims have real clinical implications worth examining.

Does the science back this up?

Mostly yes, with important caveats. A level of 200 ng/dL is unambiguously low by any clinical standard, the symptom profile he describes is consistent with hypogonadism, and the injection-versus-pellet pharmacokinetics he describes are broadly accurate. The gains claim is harder to verify but plausible.

The Endocrine Society defines hypogonadism as a total testosterone below 300 ng/dL on two morning measurements (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). At 200 ng/dL, he was clearly in symptomatic range. Research does show TRT improves lean mass and strength in hypogonadal men. A 2016 NEJM study (Snyder et al.) found meaningful gains in muscle mass and physical function in older men on TRT. His pellet-to-injection pharmacokinetics story also checks out: subcutaneous pellets do produce a peak around weeks 8-12 before declining (Khera et al., 2014, Journal of Sexual Medicine), while weekly or twice-weekly injections of testosterone cypionate produce more stable trough levels.

What did they get wrong (or right)?

The "1,000-1,200 ng/dL" target claim deserves scrutiny. He's not wrong that some clinicians aim there, but calling it a broadly accepted "peak level for guys" overstates the consensus. The Endocrine Society's target is the mid-normal range, roughly 400-700 ng/dL. Levels above 1,000 are associated with increased hematocrit, erythrocytosis, and cardiovascular risk in some populations (Basaria et al., 2010, NEJM, which had to halt a TRT arm early due to adverse cardiac events in older men).

His point about endogenous testosterone suppression is actually reasonable. Yes, exogenous testosterone suppresses the HPG axis and reduces natural production. But if your baseline is 200 ng/dL and you're symptomatic, that suppression trade-off is a legitimate clinical conversation, not automatically a reason to avoid treatment. He frames it colloquially but the logic is defensible. He also correctly notes that pellet costs are higher, which is a documented access barrier in real-world TRT management.

What should you actually know?

If you are considering TRT, the process matters as much as the decision. A single testosterone reading is not enough. Guidelines call for two fasting, morning tests plus LH and FSH levels to determine whether low testosterone is primary (testicular) or secondary (pituitary). Treating without that workup can mask treatable conditions like pituitary tumors.

The suppression concern he dismisses is real for men who want to preserve fertility. TRT shuts down sperm production in most men within months (Contraception, Nieschlag et al., 2010). If having children is on the table, that conversation needs to happen before starting. For men not concerned with fertility, his framing is less problematic but still incomplete. Monitoring hematocrit, PSA, and lipids on TRT is not optional, it is part of standard-of-care management. The platform you use to access TRT should be doing that work with you.

Bottom line: personal experience or good advice?

@trtstrong is sharing a personal story and largely does so responsibly. His core narrative, low levels, symptoms, clinical treatment, sustained benefit, tracks with what the evidence supports for genuinely hypogonadal men. The 1,000-1,200 ng/dL target is the shakiest claim here, not because it's impossible to reach safely, but because presenting it as a universal goal without context on monitoring and risk is the kind of shortcut that gets people into trouble. Take the experience for what it is: one data point from one man who was clearly undertreated before TRT. Get your own labs. Work with a clinician who monitors you.